Nabriva Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
H. Hogan
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.5yrs |
| CEO ownership | n/a |
| Management average tenure | 1.6yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Nabriva Therapeutics to effect 1-for-25 reverse stock split
Sep 15Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
Jul 18Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022
Apr 04
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts
Aug 11We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation
Jul 22Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation
May 08When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?
Feb 16Nabriva Therapeutics announces proposed public offering
Dec 10Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China
Dec 07Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation
Nov 08CEO
H. Hogan (61 yo)
1.5yrs
Tenure
Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from Februa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 7.3yrs | US$40.00k | no data | |
| Chief Executive Officer | 1.5yrs | no data | no data | |
| Chief Financial Officer | 1.6yrs | no data | no data |
1.6yrs
Average Tenure
64yo
Average Age
Experienced Management: NBRV.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | 7.6yrs | US$40.00k | no data | |
| Independent Chairman of the Board | 7.6yrs | US$90.00k | no data | |
| Independent Director | 3.6yrs | US$50.00k | no data | |
| Independent Director | 7.6yrs | US$65.00k | no data | |
| Director | 3.8yrs | US$579.23k | no data | |
| Independent Director | 7.6yrs | US$55.00k | no data | |
| Director | 6.4yrs | US$753.56k | no data | |
| Independent Director | 3.6yrs | US$47.50k | no data |
7.0yrs
Average Tenure
64.5yo
Average Age
Experienced Board: NBRV.F's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:30 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nabriva Therapeutics plc is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Kevin Kedra | G. Research, LLC |